All In Biotech

Free tool

FAERS Monitor: Povidone Iodine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019522 or its brand name (Povidone Iodine, Povidone-Iodine). Reports on generic versions are filed under their own applications.

Reports

2,059

Serious

1,932

94% of reports

Hospitalization

772

Death reported

361

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use320
  • endophthalmitis229
  • drug ineffective191
  • nausea191
  • rash187
  • pain176
  • drug hypersensitivity166
  • product use in unapproved indication144
  • confusional state142
  • rheumatoid arthritis142
  • pericarditis137
  • wound135
  • type 2 diabetes mellitus134
  • c-reactive protein increased133
  • pemphigus132

Reports by year received

View as table
YearReports
200455
200527
200635
200751
200859
200953
201059
201173
201285
201349
201453
201541
201666
2017120
2018109
2019193
2020104
202155
2022169
2023106
2024142
2025216
2026139

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,100 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endophthalmitisSignal229405.4357.888,485
pemphigusSignal132109.092.313,878
pericarditisSignal13784.071.411,068
woundSignal13549.642.16,354
type 2 diabetes mellitusSignal13440.834.65,153
c-reactive protein increasedSignal13337.531.84,676
rheumatoid arthritisSignal14212.810.91,538
confusional stateSignal1429.07.71,006
drug hypersensitivitySignal1668.87.61,144
product use in unapproved indicationSignal1445.95.1593
rashSignal1874.43.8495
off label useSignal3203.73.4665
painSignal1762.92.5228
nauseaSignal1912.52.2171
drug ineffective1911.51.331

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.